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Abstract. Background: In Germany, adverse drug reactions and events cause 
hospitalizations, which lead to numerous thousands of deaths and several million 
Euros in additional health costs annually. Objectives: Approximately one in two 
deaths could be avoided by an appropriate system for risk analysis of drugs. 
Methods: The integration and storage of several data sources from life sciences are 
an ongoing need to address various questions with respect to drug therapy. A 
software architecture for data integration was implemented in order to build up a 
new data warehouse named KALIS-DWH, which includes pharmacological, 
biomolecular and patient-related data. Results: Based on this comprehensive 
KALIS-DWH, an eHealth system named KALIS for biomedical risk analysis of 
drugs was implemented. The task-specific modules of KALIS offer efficient 
algorithms for analyzing medication and supporting decision-making in drug 
therapy. Conclusion: KALIS is meant to be a web-based information system for 
health professionals and researchers. KALIS provides comprehensive knowledge 
and modules for risk analysis of drugs, which can contribute to minimizing 
prescribing errors.  
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1. Introduction 
The prevalence of multimorbidity will rise with the predicted global demographic change 
and the associated aging of the population. Multimorbid patients are treated with 
complex polypharmacy, which is commonly defined as permanent intake of more than 
five drugs [1]. Polypharmacy increases the risk of drug-related problems (DRP), 
including inadequate prescribing (IP), medication errors, and adverse drug reactions and 
events (ADR, ADE), which in turn are frequent causes of hospitalization and death [2]. 
In Germany, several studies [3,4] reported a hospitalization rate of 3-7% due to ADE, 
which led to more than 16,000 drug-related deaths [5] and more than 400 million Euros 
in additional health costs [6] annually. Additionally, 340,000 to 720,000 patients suffer 
consequential damages on account of ADE [5]. Up to 50% of all ADE-related 
hospitalizations are judged to be preventable by avoiding prescribing errors [7]. The 
causes of prescribing errors in patients are multifaceted and complex, including 
prescribers lack of medication-related information or insufficient knowledge of geriatric 
pharmacotherapy. Furthermore, the pharmacotherapy is frequently not perceived as a 
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risk process and thus, potential drug-drug interactions (DDI) and drug-disease 
interactions remain undetected, which are associated with a significantly increased risk 
for ADE. On the other hand, most the therapeutic guidelines advise prescribing of each 
drug individually and do not consider multiple diseases to discuss the applicability of 
their recommendations. Therefore, the evidence is increasing that polypharmacy 
resulting from recommendations of different therapeutic guidelines can potentially cause 
more damage than benefit in multimorbid patients.  
A variety of commercial or scientific approaches brought up numerous drug-related 
databases and systems. These available databases such as ifap index®KLINIK [8], 
DRUG-REAX® [9], Lexi-Interact® [10] and Drug Interaction Facts® [11] have shown 
to contribute substantially to minimizing prescribing errors, but also have revealed a 
large discrepancy in number and clinical relevance of detected DDI [12]. Accordingly, 
at least two drug-related databases are needed to meet the high medical-pharmacological 
requirements of a reliable analysis of drugs for treatment in patients. Moreover, 
optimizing polypharmacy without using additional biomolecular information remains 
still complicated. A comprehensive and patient-specific analysis needs to include 
biomolecular data for gaining a better understanding of the underlying mechanism of 
drug action and the potential impact on the disease. Especially in the case of dose 
adjustment of psychotropic drugs, information on pharmacogenetic interactions is 
essential to health professionals trying to improve the individual response and thus, to 
reduce side effects.  
For this purpose, we have developed an eHealth system named KALIS for 
biomedical risk analysis of drugs. The underlying data warehouse named KALIS-DWH 
integrates drug-related pharmacological, biomolecular, and patient-related databases. 
This data warehouse enables KALIS to provide task-specific modules for analysis and 
visualization of drug risks. 
2. Methods 
2.1. Architecture of the system 
KALIS was implemented as a web-based information system for health professionals 
and researchers. It is platform independent and available via the internet by an extended 
client/server architecture (Figure 1). The client/server architecture ensures a dividing into 
four functional layers: 
• Request and presentation layer, the clients 
• Application layer, the web server 
• Data storage layer, the database system and the interface 
• Data integration layer, the software infrastructure for data integration 
An arbitrary set of user inputs is sent via an asynchronous HTTP(S)-request to the 
Apache web server. On the server side, a database system and PHP scripts were used to 
generate static HTML pages for visualizing the results of the analysis on basis of the data 
warehouse KALIS-DWH and/or the external data warehouse system DAWIS-M.D [13]. 
This development approach uses the concept of modularity and scalability to provide 
a flexible and location independent access to the information services offered by KALIS 
to a high number of users. In turn, the modularity covers the maintainability and 
extensibility with regard to the steadily increasing requirements.  
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Figure 1. Client/Server architecture of the system KALIS. 
2.2. Data storage and integration 
The growing specialization of distributed and heterogeneous data sources with 
corresponding different formats represent a major challenge in the integration. For this 
reason, a software infrastructure for data integration was developed. As summarized in 
Figure 2, the architecture is divided into integration, conception and merging layer. 
Applying this integration infrastructure, a consistent data warehouse named KALIS-
DWH was created, which has a uniform data structure and provides comprehensive 
information to deal with various questions regarding drug therapy. The data warehouse 
KALIS-DWH includes eight different data sources from life sciences:  
• three pharmacological databases (grey): ABDAMED [14], ROTE LISTE® 
[15], and GELBE LISTE® [16]; 
• three international databases with patient-related case reports of ADE (red): 
FAERS [17], ARD [18] and DPD [19];  
• two newly developed databases (green): CYP-P450 and PRISCUS-Liste. The 
databases CYP-P450 and PRISCUS-Liste are based on information sources 
from scientific literature such as publications about pharmacogenetic 
interactions [20] or inappropriate drugs [21].  
Due to different exchange formats (XML, ASCII, CSV, MDB) and license models, 
specific SAX2-Parser were implemented in Java for each data source. These parsers were 
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performed to extract the datasets, transform the data into the respective MySQL database 
and to load it efficiently into KALIS-DWH. Furthermore, relevant metadata for user 
management and data analysis is stored in a separate database. 
The pharmacological databases of KALIS-DWH were fused with the biomolecular 
databases such as DrugBank [22], SIDER [23] or KEGG [24] via the interface to 
DAWIS-M.D. This biomolecular data can be used for knowledge discovery of the 
underlying mechanism of drug action or the potential impact on the disease. The 
integration of the biomolecular data sources into DAWIS-M.D. was performed by 
implementing SAX-Parser in Java and using the software kit BioDWH [25]. National 
and international standards were used for coding, mapping and assignment of medical 
information such as drugs, therapeutic indications, diseases and side effects. These 
standards include medical-pharmacological classifications and terminologies such as 
ATC [26], ICD-10 [27] or MedDRA [28]. In this way, the homogeneous data warehouses 
KALIS-DWH and DAWIS-M.D. provide pharmacological and biomolecular 
information for efficient and goal-oriented risk analysis of drugs. The standardized codes 
support the accuracy of data inputs and processing as well as a simple data exchange and 
uniform communication between KALIS and end user.  
2.3. Conception of new databases 
Much of the information on pharmacogenetic interactions and inappropriate medications 
is spread across literature and the internet. Aggregating of this knowledge into databases 
and merging it with important therapeutic data makes the risk analysis more efficient. 
Therefore, two new databases named CYP-P450 and PRISCUS-Liste were created.  
2.3.1. CYP-P450 
The most important pharmacokinetic interactions occur at the level of biotransformation. 
The family of Cytochrome P450 Enzymes (CYP) plays a crucial role in the 
biotransformation of many substances. The inter-individual variability in the 
biotransformation of drugs by enzyme induction or inhibition and genetic 
polymorphisms also indicate a significant issue of drug therapy. Based on these facts, a 
new database CYP-P450 was designed, which contains information on interactions 
between substances and CYP enzymes in the liver and kidney. Currently, the database 
contains 680 substrates, 30 enzymes, 2,661 interactions and 738 references. This data is 
primarily based on the results of the literature research of Dippl [20].  
2.3.2. PRISCUS-Liste 
Due to age-changing pharmacokinetics and pharmacodynamics as well as increasing 
multimorbidity, numerous drugs are considered as potentially inappropriate in elderly 
patients (> 65 years). For this purpose, the Priscus List was created as a part of the joint 
project “PRISCUS” [21], which was funded by the German Federal Ministry of 
Education and Research (BMBF). The Priscus List includes 83 drugs of 18 drug classes 
that are adapted to the German drug market. The risk of these drugs for any side effects 
or age-related complications prevails the medical benefits. Therefore, a new database 
PRISCUS-Liste was designed, which contains all the information on these 83 potentially 
inadequate drugs (e.g.: reason, therapy alternatives). 
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Figure 2. Software infrastructure for data integration. 
2.4. Data analysis 
The server-side application logic is responsible for algorithmic analyzing, processing and 
visualizing of the data from KALIS-DWH. The focus is on the web-based availability of 
drug-related information associated with patient-specific risk factors or therapeutic 
targets. Accordingly, a wide range of task-specific modules for decision support in drug 
therapy is offered by KALIS. The major modules are described in the following: 
1) Pharmacological risk-check 
This module enables users to check the patient-related data for drug-drug 
interactions, contra-indications, side effects, drug allergies, double prescriptions 
and drug-food interactions. Using two recognized databases, ABDAMED and 
ROTE LISTE, the quality of interactions data is significantly increased, 
resulting in a higher rate of detection and clinical relevance of the interactions. 
For further support and improvement of medication process, alternative 
therapies are also determined and proposed to the user. 
2) Inadequate medications 
This module allows users to check the prescription of elderly patients (> 65 
years) for potentially inadequate drugs. 
3) Pharmacogenetic drug interactions 
Many drugs inhibit or induce the activity of CYP, which in turn is important to 
health professionals trying to give an appropriate dosage of those drugs. These 
interactions between substrates and the family of Cytochrome P450 Enzymes 
(CYP) can be predicted by this module. 
4) Adverse drug events 
Incident reports of ADE can provide new impulses in the identification of 
potential trigger of side effects if they are not included in medicinal product’s 
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professional information already. This module supports the user search for ADE 
reports of a drug considering the patient characteristics (age, gender, etc.). 
5) Patient-specific medication assistant in hypertension 
This module assists in the computing of patient-specific diagnostic scores 
(PIDS) in hypertension by using evidence-based therapeutic guidelines [29] and 
individual patient data (age, blood pressure, gender, etc.). The predictive PIDS 
defines the suitability of the drug for the treatment of hypertension.   
6) Diagnoses-based drugs-check 
With this module, the corresponding medications of the entered diagnoses can 
be checked for adverse drug-drug interactions. Due to the preventive 
identification of interactions and their measures, prescribing errors can be 
avoided.  
7) Molecular risk-check 
Besides the pharmacological risk analysis of drugs (1-5), this module gives 
insight into the underlying biomedical networks where drugs interact at the 
biomolecular level. It includes various search forms for the analysis of drug-
drug interactions, drug-molecule interactions and side effects using additional 
biomolecular data via an interface to the partner system GraphSAW [30].  
These comprehensive modules can contribute to pinpoint risks of drugs at 
pharmacological and biomolecular level.  
3. Results 
Prescribing errors in patients and the corresponding several thousands of drug-related 
deaths could be avoided by an appropriate system. There is still a deficiency of 
consistency and grading of DDI due to the lack of standardization of the terminology 
used to classify DDI which to base the analysis of the clinical relevance of DDI. 
Currently, biomolecular information is hardly considered in the decision-making of the 
prescribing process. 
With KALIS we presented a new eHealth system for biomedical risk analysis of 
drugs. The underlying homogeneous data warehouse KALIS-DWH includes several 
pharmacological, biomolecular, and patient-related data sources. The developed 
software infrastructure ensures a flexible integration and merging of different 
heterogeneous data sources. The large-scale KALIS-DWH enables to address specific 
and complex questions regarding drug therapy. The task-specific modules of KALIS 
offer efficient therapeutic algorithms for the analysis of adverse drug reactions. Health 
professionals can analyze the prescriptions and manage various drug risks: DDI, contra-
indications, side effects, drug allergies, double prescriptions, drug-food interactions, IP, 
and drug-CYP interactions. In addition, the medication assistant in hypertension and the 
preventive diagnoses-based drugs-check can support the decision-making in order to 
avoid prescribing errors. Moreover, the molecular risk-check gives insight into the 
efficacy of the biochemical drug mechanisms for analysis and optimization of 
polypharmacy.  
In conclusion, substantial improvements in prescribing quality can be achieved by 
using KALIS. Potential risks of drug-related problems of polypharmacy in multimorbid 
patients can be reduced and thus, consequential damage, deaths and costs can be 
prevented.  
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4. Discussion 
The consistency of the drug-drug interactions and drug side effects among the integrated 
pharmacological and biomolecular databases was analyzed in a former study [30, 31]. 
This comparative assessment showed important discrepancies in comprehensiveness and 
accuracy of DDI and side effects among the databases ABDAMED, DrugBank and 
SIDER. Apart from that, the data quality increased by merging knowledge of these 
databases. The study showed that this combination of databases increases the information 
density of DDI (> 30%) and side effects (> 60%). This results in higher rate of detection 
and clinical relevance in a risk analysis. In addition, the study indicated that at least one 
in a hundred of side effects represents a drug-induced disease. However, biomolecular 
databases are intended for scientific research purposes given the facts of errors and 
inconsistencies of content. Moreover, the extent of side effects differs in each patient due 
to several impact factors such as inter-individual genetic diversity, diet or environment. 
Some of these aspects such as patient’s functional level, values, and preferences can be 
considered appropriately by implementing an interface between KALIS and a 
computerized physician order entry (CPOE). A CPOE uses established standards, e.g. 
Health Level 7 (HL7), to provide the patient-related data for the exchange and to address 
clinical needs in support of prescribing process.  
5. Availability and requirements 
KALIS is available at http://tunicata.techfak.uni-bielefeld.de/kalis/. Access to the system 
is restricted by the commercial databases and will be enabled by a request to the authors. 
To fully access all modules of the system, the browser versions such as Internet Explorer 
9+ or Mozilla Firefox 23+ should first be installed.  
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